Italian Start-up CellPly Snares $2.8M Seed Investment | GenomeWeb

NEW YORK (GenomeWeb News) – Start-up CellPly has attracted €2 million ($2.8 million) in seed capital investment to support development of its technology for determining patient response to oncology therapeutics.

Italian Angels for Growth, Zernike Meta Ventures, and Atlas Seed made the investment into Bologna, Italy-based CellPly in order to support the firm's completion of its diagnostics platform, which is being developed to allow clinicians to assess in vitro a patient's cellular response to cancer treatments, such as chemotherapy and monoclonal antibodies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.